Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck’s Q3 Results on Oct. 29

Merck (NYSE:MRK) reports third-quarter results on Thursday, Oct. 29. KEYTRUDA still anchors the business, but I’ll be watching whether newer launches are growing fast enough to cushion the drug’s 2028 patent loss. New Launches Are Carrying More of the Load Last quarter, revenue rose 5.07% to $16.61 billion, beating the $16.37 billion consensus. The non-GAAP […]